Phase 3Recruiting
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (COLCOT-T2D)
- Sponsor
- Montreal Heart Institute (Academic or other)
- Enrolment
- 10,000 planned
- Conditions
- Diabete Type 2; Cardiovascular Diseases
- Interventions
- Aspirin; Aspirin Placebo; Colchicine; Colchicine Placebo
- Ages
- adults, older adults
- Registry
- NCT05633810
Full record on ClinicalTrials.gov
From the registry
To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.
Primary outcomes
- First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.
History
Primary completion expected
Last registry update
Started
Registered